ScripWhen Zevra Therapeutics, then known as KemPharm, bought arimoclomol for peanuts with its acquisition of Orphazyme in 2022, it looked like a great bit of business and further confirmation has come wi
Pink SheetHarmony Biosciences plans to accelerate Phase III development of a high-dose pitolisant formulation (pitolisant HD) in idiopathic hypersomnia (IH) after the US Food and Drug Administration turned down
ScripHarmony Biosciences plans to accelerate Phase III development of a high-dose pitolisant formulation (pitolisant HD) in idiopathic hypersomnia (IH) after the US Food and Drug Administration turned down
Pink SheetThe US Food and Drug Administration maintained a high rate of complete response letter actions for novel agent applications in 2024, but recent history suggests that many of the 16 CRL recipients will